Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immuneering CorporationNASDAQ: IMRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $10.65B rose 92695.6% year over year, ahead of the +22061.7% change in trailing-twelve-month research & development. Sequentially, it rose 114185.0% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +92695.6% holds above the trailing-twelve-month pace of +22061.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 42.05M USD
- Year-over-year change
- -12.3%
- 4-year CAGR
- +12.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.05M | -12.3% |
| FY2024 | 2024-12-31 | 47.96M | +15.2% |
| FY2023 | 2023-12-31 | 41.62M | +14.8% |
| FY2022 | 2022-12-31 | 36.27M | +36.6% |
| FY2021 | 2021-12-31 | 26.54M | — |
Research & Development vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 research & development of $10.68B is the highest of the 11 companies compared; the peer median is $74.8M.
- Its year-over-year change of +22061.7% is the highest of 11, against a peer median of -10.4%.
- Over three fiscal years its annual growth of +5.1% compares with a peer median of -3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $76.25M | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
| LTM Mar 2026 | $62.37M | -24.6% | -10.1% | 27721.8% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
| LTM Mar 2026 | $40.3M | -12.6% | +4.1% | — | |
| Peer median (excluding IMRX) | $74.8M | -10.4% | -3.8% | 420.5% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.08M | 316.95K | 0 | 0 | 0 |
| Cost of Revenue | 1.15M | 158.12K | 0 | 0 | 698.89K |
| Gross Profit | 926.89K | 158.83K | 0 | 0 | (698.89K) |
| Gross Margin | 44.6% | 50.1% | — | — | — |
| Research & Development | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M |
| Selling, General & Admin | 8.27M | 15.61M | 16.76M | 16.08M | 17.3M |
| Operating Expenses | 34.81M | 51.9M | 58.41M | 64.07M | 58.68M |
| Depreciation & Amortization | 159.07K | 277.25K | 352.08K | 385.07K | 698.89K |
| EBITDA | (33.68M) | (51.47M) | (58.06M) | (63.69M) | (55.33M) |
| EBITDA Margin | -1619.5% | -16238.4% | — | — | — |
| Operating Income | (33.89M) | (51.74M) | (58.41M) | (64.07M) | (59.38M) |
| Operating Margin | -1629.2% | -16325.8% | — | — | — |
| Interest Income | 169.9K | 1.01M | 3.61M | 2.59M | 3.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 42.83K | 1.23M | 4.94M | 3.03M | 3.35M |
| Income Before Tax | (33.84M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Pre-Tax Margin | -1627.1% | -15937.4% | — | — | — |
| Income Tax Expense | (307.49K) | 0 | 0 | 0 | 0 |
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Net Margin | -1612.3% | -15937.3% | — | — | — |
| EPS (Basic) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| EPS (Diluted) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| Weighted Avg Shares | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
| Weighted Avg Shares (Diluted) | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.